NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x
Houston, Texas--(Newsfile Corp. - August 12, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) reported encouraging Phase 2a results for intranasal NEO100 in patients with recurrent IDH1-mutant high-grade glioma, showing a 48.9% six-month progression-free survival rate compared with a 20% historical benchmark. The result was nearly 2.5 times the historical benchmark and was statistically significant at p=0.0047. The study enrolled patients with advanced recurrent Grade III or Grade IV glioma...
2026-08-12 9:25 AM EDT
NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence
Houston, Texas--(Newsfile Corp. - August 11, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) is set up for a potential high impact catalyst day with what market observers are describing as a classic triple confluence setup. The company will release topline Phase 2a results for its intranasal NEO100 therapy in recurrent IDH1-mutant high-grade glioma, a difficult-to-treat form of brain cancer on Wednesday, August 12 at 8:30 a.m. ET. The three factors market participants should watch are its...
2026-08-11 8:44 AM EDT
WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy
Houston, Texas--(Newsfile Corp. - June 22, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) recently achieved what many biotechnology companies spend years attempting to secure: international regulatory validation for a novel therapeutic candidate before obtaining later-stage U.S. approvals. The Department of Health - Abu Dhabi's Investigational New Drug (IND) authorization for NEO212 marks the first international regulatory clearance for the company's oral perillyl alcohol-temozolomide...
2026-06-22 8:45 AM EDT
WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates
Houston, Texas--(Newsfile Corp. - June 15, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) continues to attract attention within the biotechnology sector as the Company advances its neuro-oncology pipeline and strengthens its balance sheet ahead of anticipated clinical development milestones. NeOnc's new Securities Purchase Agreement with accredited investors provides for up to $5 million through the issuance of Series A Convertible Preferred Stock. The financing arrives as NeOnc continues...
2026-06-15 8:35 AM EDT
The Race to Defeat Brain Cancer Could Become One of the Biggest Biotech Stories of the Decade
Houston, Texas--(Newsfile Corp. - June 9, 2026) - For years, artificial intelligence has dominated conversations surrounding the future of healthcare innovation. Yet beyond the AI-driven headlines, another potentially groundbreaking revolution is unfolding in one of medicine's most challenging arenas: the fight against brain cancer. As researchers pursue new approaches to treat aggressive and often treatment-resistant tumors, emerging innovators such as NeOnc Technologies Holdings (NASDAQ:...
2026-06-09 8:45 AM EDT